hansoh pharma news - Search News

Merck, China and Hansoh

Merck enters obesity drug race in pact with Chinese pharma Hansoh

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at weight loss and other cardio metabolic conditions.

Reuters on MSN · 18h

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.

Al Bawaba News · 45m

Merck comes up with weight loss drug deal worth $2 billion with China

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes an upfron

FierceBiotech20h

Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

13h

What's Going On With Viking Therapeutics Stock On Wednesday?

Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license ...

19h

Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535

(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Merck, China and Hansoh

Trending now

Related topics